Giant and large basal cell carcinoma treated with topical photodynamic therapy

Laura Eibenschutz, Samantha Marenda, Pier Luigi Buccini, Paola De Simone, Angela Ferrari, Giustino Mariani, Vitaliano Silipo, Caterina Catricalà

Research output: Contribution to journalArticlepeer-review


Basal cell carcinoma (BCC) is the most common cancer affecting Caucasians and, due to its large size or to the poor condition of the patient, it can be difficult to treat it with conventional therapies: in these cases photodynamic therapy with methyl aminolevulinate (MAL-PDT) may represent a good option. A retrospective non-comparative follow-up study was performed to test the response of giant and large BCC to MAL-PDT. Twelve patients with 14 giant BCC (≥ 5 cm) and 5 patients with 5 large BCC (4-5 cm) were treated with MAL-PDT; they were evaluated 6 months after the end of the treatment to define the initial cure rate, and then at 12 and 36 months for the follow-up. At 6 months the initial cure rate for the 19 BCCs was 95% and at 36 months the overall long-term cure rate was 66%. The follow-up will last up to 5 years. MAL-PDT is a valid option for the treatment of giant and large BCC.

Original languageEnglish
Pages (from-to)663-666
Number of pages4
JournalEuropean Journal of Dermatology
Issue number6
Publication statusPublished - Nov 2008


  • Giant basal cell carcinoma
  • Methyl 5-aminolaevulinate
  • Topical photodynamic therapy

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Giant and large basal cell carcinoma treated with topical photodynamic therapy'. Together they form a unique fingerprint.

Cite this